drugset
drugset / Trial / NCT03776539

A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

NCT03776539 ↗

Phase 1 Completed 24 enrolled Eloxx Pharmaceuticals, Inc. Syneos Health · collab
NaSingle-groupOpen-labelTreatment

Summary

Phase 1 - Pharmacokinetics in Patients with Impaired Renal Function

Timeline

Start
2019-01-04
Primary completion
2019-07-30
Completion
2019-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ELX-02 Small molecule — —

Indications

impaired renal function disease